News coverage about Intrexon Corporation (NYSE:XON) has been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intrexon Corporation earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.5894594386436 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Technical Facts to Know: Intrexon Corporation (XON) traded -51.23% away from 52-Week High – Voice Of Analysts (analystsbuzz.com)
- Is The Stock More Volatile Than The Market? – Intrexon Corporation, (NYSE: XON) – Stock Watch (stocksnewstimes.com)
- Synthetic Biology Market – Trends, 2024 (reports.pr-inside.com)
- Intrexon : Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia (4-traders.com)
- Intrexon to Announce Third Quarter 2017 Financial Results on November 9th (finance.yahoo.com)
Shares of Intrexon Corporation (NYSE XON) traded up $0.61 during trading hours on Friday, reaching $16.43. 803,290 shares of the company traded hands, compared to its average volume of 1,054,833. Intrexon Corporation has a one year low of $15.62 and a one year high of $32.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.25 and a current ratio of 2.45.
Intrexon Corporation (NYSE:XON) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million during the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.42) EPS. equities analysts forecast that Intrexon Corporation will post -0.84 EPS for the current year.
Several brokerages recently commented on XON. Zacks Investment Research downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub downgraded shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. JMP Securities reiterated an “outperform” rating and set a $42.00 price target on shares of Intrexon Corporation in a report on Thursday, October 5th. Northland Securities set a $30.00 price target on shares of Intrexon Corporation and gave the company a “buy” rating in a report on Monday, August 7th. Finally, Griffin Securities reiterated a “buy” rating and set a $55.00 price target on shares of Intrexon Corporation in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $43.20.
In related news, Director Dean J. Mitchell acquired 5,000 shares of the stock in a transaction on Friday, August 11th. The stock was bought at an average cost of $18.33 per share, with a total value of $91,650.00. Following the transaction, the director now directly owns 18,103 shares in the company, valued at $331,827.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Randal J. Kirk acquired 132,625 shares of the stock in a transaction on Friday, August 11th. The stock was bought at an average cost of $18.85 per share, with a total value of $2,499,981.25. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 144,569 shares of company stock valued at $2,719,429. 55.10% of the stock is owned by corporate insiders.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
What are top analysts saying about Intrexon Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intrexon Corporation and related companies.